Search

Displaying results 5421 - 5430 of 9118 in total
  1. Drug

    Tifcemalimab

    go.drugbank.com/drugs/DB18914
    Investigational

    Tifcemalimab is under investigation in clinical trial NCT06095583 (Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell

  2. Drug

    Tiamenidine

    go.drugbank.com/drugs/DB19607
    Experimental

    Tiamenidine is a small molecule drug. The usage of the INN stem '-nidine' in the name indicates that Tiamenidine is a a2 adrenoreceptor agonist. … Tiamenidine has a monoisotopic molecular weight of 215.03 Da.

  3. Drug

    Libivirumab

    go.drugbank.com/drugs/DB17748
    Experimental

    Libivirumab is an investigational monoclonal antibody. … It is one of the active ingredients in HepeX-B, a drug product containing two human monoclonal antibodies to the hepatitis B virus (HBV) surface antigen.[A259202]

    Synonyms: HBV-Ab 17
  4. Drug

    TAK-754

    go.drugbank.com/drugs/DB17850
    Investigational

    TAK-754 is an adeno-associated virus serotype 8 vector (AAV8) expressing B domain deleted codon optimized factor VIII. Developed by Takeda, it is being investigated for the treatment of hemophilia A.

  5. Drug

    PR1 leukemia peptide vaccine

    go.drugbank.com/drugs/DB15276
    Investigational

    PR1 leukemia peptide vaccine is under investigation in clinical trial NCT00513578 (Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome).

  6. Drug

    SAR-125844

    go.drugbank.com/drugs/DB15382
    Investigational

    SAR-125844 is under investigation in clinical trial NCT01391533 (Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors).

  7. Drug

    Birtamimab

    go.drugbank.com/drugs/DB16414
    Investigational

    Birtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis).

  8. Drug

    ENTR-601-44

    go.drugbank.com/drugs/DB17836
    Investigational

    ENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]

  9. Drug

    GB-13

    go.drugbank.com/drugs/DB18387
    Experimental

    GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A.

  10. Drug

    PAS-004

    go.drugbank.com/drugs/DB18611
    Investigational

    PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.